MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Gilead Sciences Inc.

Ouvert

SecteurSoins de santé

103.22 -3.79

Résumé

Variation du prix de l'action

24h

Actuel

Min

100.88

Max

107.3

Chiffres clés

By Trading Economics

Revenu

530M

1.8B

Ventes

29M

7.6B

P/E

Moyenne du Secteur

274.553

57.333

BPA

1.9

Rendement du dividende

3.02

Marge bénéficiaire

23.557

Employés

17,600

EBITDA

-655M

3.1B

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+9.79% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

3.02%

2.63%

Date du Prochain Dividende

26 juin 2025

Date du Prochain Détachement de Dividende

13 juin 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

8.7B

130B

Ouverture précédente

107.01

Clôture précédente

103.22

Score Technique

By Trading Central

Confiance

Bullish Evidence

Gilead Sciences Inc. Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 avr. 2025, 20:17 UTC

Résultats

Gilead Sciences Swings to 1Q Profit, But Slashes FY25 EPS Guidance

11 févr. 2025, 21:17 UTC

Résultats

Gilead Sciences 4Q Profit Up on HIV Product Sales, Dividend Raised

24 avr. 2025, 20:08 UTC

Résultats

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

24 avr. 2025, 20:02 UTC

Résultats

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

24 avr. 2025, 20:02 UTC

Résultats

Gilead Sciences: As of March 31, 2025, $7.9 Billion of Cash and Cash Equivalents Compared to $10.0 Billion as of Dec. 31, 2024 >GILD

24 avr. 2025, 20:02 UTC

Résultats

Gilead Sciences 1Q Rev $6.67B >GILD

24 avr. 2025, 20:02 UTC

Résultats

Gilead Sciences: 1Q Product Gross Margin Was 76.7% Compared to 76.6% in Same Period in 2024 >GILD

24 avr. 2025, 20:02 UTC

Résultats

Gilead Sciences: During 1Q Generated $1.8 Billion in Operating Cash Flow >GILD

24 avr. 2025, 20:02 UTC

Résultats

Gilead Sciences 1Q Adj EPS $1.81 >GILD

24 avr. 2025, 20:02 UTC

Résultats

Gilead Sciences: 1Q Lower Veklury (Remdesivir) and Oncology Sales Offset by Higher HIV and Liver Disease Sales >GILD

24 avr. 2025, 20:02 UTC

Résultats

Gilead Sciences Sees 2025 EPS $5.65-EPS $6.05 >GILD

24 avr. 2025, 20:02 UTC

Résultats

Gilead Sciences 1Q EPS $1.04 >GILD

24 avr. 2025, 20:02 UTC

Résultats

Gilead Sciences 1Q EPS $1.04 >GILD

24 avr. 2025, 20:02 UTC

Résultats

Gilead Sciences Sees FY EPS $5.65-EPS $6.05 >GILD

24 avr. 2025, 20:02 UTC

Résultats

Gilead Sciences 1Q Total Liver Disease Sales $758M >GILD

24 avr. 2025, 20:02 UTC

Résultats

Gilead Sciences 1Q Net $1.32B >GILD

24 avr. 2025, 20:02 UTC

Résultats

Gilead Sciences 1Q Adj EPS $1.81 >GILD

24 avr. 2025, 20:02 UTC

Résultats

Gilead Sciences Sees FY Adj EPS $7.70-Adj EPS $8.10 >GILD

24 avr. 2025, 20:02 UTC

Résultats

Gilead Sciences 1Q Rev $6.7B >GILD

11 avr. 2025, 09:30 UTC

Actualités

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

19 mars 2025, 14:50 UTC

Actualités

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

28 févr. 2025, 12:00 UTC

Actualités

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

11 févr. 2025, 22:13 UTC

Market Talk
Résultats

Gilead's HIV Segment Buoying Product Sales Amid Covid Losses -- Market Talk

11 févr. 2025, 21:06 UTC

Résultats

Gilead Beats Earnings Estimates on Strong HIV Sales -- Barrons.com

11 févr. 2025, 21:02 UTC

Résultats

Gilead Sciences Planning for Potential Launch of Lenacapavir for HIV PrEP in Summer 2025>GILD

11 févr. 2025, 21:02 UTC

Résultats

Gilead Sciences Sees 2025 EPS $5.95-EPS $6.35 >GILD

11 févr. 2025, 21:02 UTC

Résultats

Gilead Sciences Raises Dividend to 79c Vs. 77c >GILD

11 févr. 2025, 21:02 UTC

Résultats

Gilead Sciences Sees 2025 Product Sales Excluding Veklury $26.8B - $27.2B>GILD

11 févr. 2025, 21:02 UTC

Résultats

Gilead Sciences Raises Dividend 2.6%>GILD

11 févr. 2025, 21:02 UTC

Résultats

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

Comparaison

Variation de prix

Gilead Sciences Inc. prévision

Objectif de Prix

By TipRanks

9.79% hausse

Prévisions sur 12 Mois

Moyen 116.79 USD  9.79%

Haut 140 USD

Bas 89 USD

Basé sur 24 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

24 ratings

18

Achat

6

Maintien

0

Vente

Score Technique

By Trading Central

105 / 106.5Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Very Strong Bearish Evidence

Long Terme

Weak Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.